COVID-19 update included
The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic

The Europe Cartilage Repair Market would witness market growth of 5.3% CAGR during the forecast period (2018 – 2024).
The tissue prevents friction between the bones, by absorbing shock in the joints. When damage is caused in the cartilage, it restricts the regular movement of the knee, causing immense pain. It generally occurs after a traumatic and twisting injury to the knee. If cartilage damage remains untreated, it would lead to knee replacement surgery.

Knee osteoarthritis is among the most common diseases, due to factors such as aging and obesity. This further enhances the demand for Cartilage repair surgery as Cartilage tissue’s ability to repair itself is very limited, as there are no blood vessels, and bleeding is vital in healing. Moreover, this growth is further supported by the constant technological advancements in the region.

Based on the modality, the Cartilage Repair market is segmented into Cell-Based and Non-Cell-Based. Cell-Based Cartilage Repair further segmented into Chondrocyte Transplantation and Growth Factor Technology. Non-Cell-Based Cartilage Repair further includes Tissue Scaffolds and Cell-Free Composites. Based on the Application, the market is segmented into Hyaline Cartilage and Fibrocartilage. The treatment type segment covers Palliative and Intrinsic Repair Stimulus. Palliative further segmented into Viscosupplementation and Debridement & Lavage. The site outlook segment covers Knee Cartilage Repair and others. Whereas, Knee Cartilage Repair covers Arthroscopic Chondroplasty, Autologous Chondrocyte, Osteochondral Grafts Transplantation, Cell-based Cartilage Resurfacing, Microfracture, and Other. Based on countries, the Cartilage Repair market segments the market into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the Europe Cartilage Repair Market. Key companies profiled in the report include B. Braun Melsungen AG, Zimmer Biomet, DePuy Synthes, Smith & Nephew plc, Stryker Corporation, Vericel Corporation, Osiris Therapeutics Inc., Arthrex, Inc., Collagen Solutions Plc, and Anika Therapeutics, Inc.